Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a systematic literature review and experts' consensus
Piero Ruscitti,Yannick Allanore,Chiara Baldini,Giuseppe Barilaro,Elena Bartoloni Bocci,Pietro Bearzi,Elisa Bellis,Onorina Berardicurti,Alice Biaggi,Michele Bombardieri,Luca Cantarini,Francesco Paolo Cantatore,Roberto Caporali,Francesco Caso,Ricard Cervera,Francesco Ciccia,Paola Cipriani,Loukas Chatzis,Serena Colafrancesco,Fabrizio Conti,Erika Corberi,Luisa Costa,Damiano Currado,Maurizio Cutolo,Salvatore D'Angelo,Francesco Del Galdo,Ilenia Di Cola,Stefano Di Donato,Oliver Distler,Bernardo D'Onofrio,Andrea Doria,Bruno Fautrel,Serena Fasano,Eugen Feist,Benjamin A Fisher,Marco Gabini,Saviana Gandolfo,Mariele Gatto,Irene Genovali,Roberto Gerli,Rosa Daniela Grembiale,Giuliana Guggino,Anna Maria Hoffmann-Vold,Annamaria Iagnocco,Francesco Salvatore Iaquinta,Vasiliki Liakouli,Menelaos N Manoussakis,Annalisa Marino,Daniele Mauro,Carlomaurizio Montecucco,Marta Mosca,Saverio Naty,Luca Navarini,Daniele Occhialini,Valeria Orefice,Federico Perosa,Carlo Perricone,Andrea Pilato,Costantino Pitzalis,Elena Pontarini,Marcella Prete,Roberta Priori,Felice Rivellese,Piercarlo Sarzi-Puttini,Raffaele Scarpa,Giandomenico Sebastiani,Carlo Selmi,Yehuda Shoenfeld,Giovanni Triolo,Francesca Trunfio,Qingran Yan,Athanasios G Tzioufas,Roberto Giacomelli
DOI: https://doi.org/10.1016/j.autrev.2024.103581
Abstract:Inflammatory rheumatic diseases are different pathologic conditions associated with a deregulated immune response, codified along a spectrum of disorders, with autoinflammatory and autoimmune diseases as two-end phenotypes of this continuum. Despite pathogenic differences, inflammatory rheumatic diseases are commonly managed with a limited number of immunosuppressive drugs, sometimes with partial evidence or transferring physicians' knowledge in different patients. In addition, several randomized clinical trials, enrolling these patients, did not meet the primary pre-established outcomes and these findings could be linked to the underlying molecular diversities along the spectrum of inflammatory rheumatic disorders. In fact, the resulting patient heterogeneity may be driven by differences in underlying molecular pathology also resulting in variable responses to immunosuppressive drugs. Thus, the identification of different clinical subsets may possibly overcome the major obstacles that limit the development more effective therapeutic strategies for these patients with inflammatory rheumatic diseases. This clinical heterogeneity could require a diverse therapeutic management to improve patient outcomes and increase the frequency of clinical remission. Therefore, the importance of better patient stratification and characterization is increasingly pointed out according to the precision medicine principles, also suggesting a new approach for disease treatment. In fact, based on a better proposed patient profiling, clinicians could more appropriately balance the therapeutic management. On these bases, we synthetized and discussed the available literature about the patient profiling in regard to therapy in the context of inflammatory rheumatic diseases, mainly focusing on randomized clinical trials. We provided an overview of the importance of a better stratification and characterization of the clinical heterogeneity of patients with inflammatory rheumatic diseases identifying this point as crucial in improving the management of these patients.